Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-200"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-200"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-2012
lpv:speaker	lp:Marie-Christine Vergiat2
lpv:spokenAs	unknown; Front de gauche pour changer d’Europe (2009-07-14--2014-06-30)3 member; CULT (2009-07-16--2012-01-18)3 member; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3 substitute; LIBE (2009-07-16--2012-01-18)3 member; DROI (2010-01-18--2012-01-18)3 substitute; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 treasurer; EUL/NGL (2009-07-14--2014-06-30)3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3
lpv:translated text	"Despite the requirement for exhaustive clinical testing and a Marketing Authorisation (MA), medicines have serious side effects which very often require hospital admission but also frequently cause deaths in the European Union. I am pleased that the European Parliament has adopted the legislation on pharmacovigilance, which strengthens provisions on this subject in European legislation concerning medicines for human use. Henceforth, patients will be able to report any undesirable effects of a medicine directly. At the same time, the setting up of a European web portal will improve information on medicines. I welcome the provisions in relation to the protection of personal data. These provisions will improve the safety and quality of medicines for patients. Nonetheless, improvement is still needed in the funding for pharmacovigilance which, at present, still remains dependent on fees paid by laboratories (and therefore on their goodwill) and in ensuring the independence of the Risk Assessment Advisory Committee in relation to the European Medicines Agency, which issues a large number of MAs for medicines in the European Union. The ball is now in the Commission’s court, particularly with regard to improving patient information leaflets."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph